|
Efficacy evaluation of the dichotomous variables |
|||||
| Efficacy variables |
Treatment group |
N |
Number (%) of participants |
p-value |
Number-needed-to-treat (95% CI) |
|
|
|||||
| 50% reduction in pain |
Topical diclofenac |
105 |
46 (43.8) |
0.004 |
5 (3–17) |
| Vehicle control |
107 |
27 (25.2) |
|||
| OMERACT-OARSI responder* |
Topical diclofenac |
105 |
69 (65.7) |
0.017 |
6 (3–33) |
| Vehicle control |
107 |
53 (49.5) |
|||
| Good or very good PGA response |
Topical diclofenac |
105 |
46 (43.8) |
<0.0001 |
4 (3–7) |
| Vehicle control |
107 |
18 (16.8) |
|||
|
*A responder is defined as a participant with ≥ 50% improvement in pain or function that was ≥ 20% of the scale, or ≥ 20% improvement in at least two of pain, function or patient global assessment that was ≥ 10% of the scale. | |||||
Baer et al. BMC Musculoskeletal Disorders 2005 6:44 doi:10.1186/1471-2474-6-44 |
|||||